SWX:NOVNPharmaceuticals
Assessing Novartis (SWX:NOVN) Valuation After Rhapsido Approval And US Manufacturing Expansion
Novartis (SWX:NOVN) just picked up European Commission approval for Rhapsido, a first in class oral treatment for chronic spontaneous urticaria, while also committing substantial US manufacturing and research spending on advanced therapies.
See our latest analysis for Novartis.
Recent news around Rhapsido approval and expanded US manufacturing sits against a share price of CHF115.64, with a 1 year total shareholder return of 29.77% and a 5 year total shareholder return of 83.35%. This...